Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1996 Jun;51(6):619–623. doi: 10.1136/thx.51.6.619

Effect of nebulised recombinant DNase on neutrophil elastase load in cystic fibrosis.

C M Costello 1, C M O'Connor 1, G A Finlay 1, P Shiels 1, M X FitzGerald 1, J P Hayes 1
PMCID: PMC1090494  PMID: 8693445

Abstract

BACKGROUND: DNA released by degenerating inflammatory neutrophils contributes to mucous plugging of airways in patients with cystic fibrosis. Neutrophil elastase, a major effector of tissue destruction in the lungs of patients with cystic fibrosis, is a highly cationic molecule which is bound and inhibited by negatively charged polyanions such as mucin and DNA in purulent sputum. Thus, the solubilisation of DNA in the airways by aerosolised recombinant DNase may remove a source of neutrophil elastase inhibition, effectively increasing elastase load. The aim of this study was to assess the effect of rhDNase therapy on neutrophil elastase load in patients with cystic fibrosis. METHODS: Blood and sputum were collected from 15 patients with cystic fibrosis before initiation of nebulised DNase therapy and at 12 weeks following therapy. The long term effects of continuous rhDNase administration were evaluated at 52 weeks for 11 of these patients. Plasma was analysed for neutrophil elastase, interleukin (IL)-8 and neutrophil elastase in complex with alpha 1-protease inhibitor (alpha 1PI). Sputum was assessed for neutrophil elastase, IL-8, and active elastase. At each visit spirometric measurements were carried out. RESULTS: Sputum elastase activity decreased at 12 weeks and was maintained at 52 weeks when a decline in total plasma elastase was also observed. Although, as expected, there was a correlation between plasma levels of total elastase and neutrophil elastase/alpha 1PI complex, the decrease in the levels of the complex at 52 weeks did not reach statistical significance. CONCLUSIONS: This study indicates that prolonged daily administration of rhDNase results in a reduction in elastase load in patients with cystic fibrosis.

Full text

PDF
619

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aitken M. L., Burke W., McDonald G., Shak S., Montgomery A. B., Smith A. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study. JAMA. 1992 Apr 8;267(14):1947–1951. [PubMed] [Google Scholar]
  2. Berger M. Inflammation in the lung in cystic fibrosis. A vicious cycle that does more harm than good? Clin Rev Allergy. 1991 Spring-Summer;9(1-2):119–142. doi: 10.1007/978-1-4612-0475-6_8. [DOI] [PubMed] [Google Scholar]
  3. Berger M., Sorensen R. U., Tosi M. F., Dearborn D. G., Döring G. Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis. J Clin Invest. 1989 Oct;84(4):1302–1313. doi: 10.1172/JCI114298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. CHERNICK W. S., BARBERO G. J., EICHEL H. J. In-vitro evaluation of effect of enzymes on tracheobronchial secretions from patients withcystic fibrosis. Pediatrics. 1961 Apr;27:589–596. [PubMed] [Google Scholar]
  5. Cantin A. Cystic fibrosis lung inflammation: early, sustained, and severe. Am J Respir Crit Care Med. 1995 Apr;151(4):939–941. doi: 10.1164/ajrccm.151.4.7697269. [DOI] [PubMed] [Google Scholar]
  6. Carré P. C., Mortenson R. L., King T. E., Jr, Noble P. W., Sable C. L., Riches D. W. Increased expression of the interleukin-8 gene by alveolar macrophages in idiopathic pulmonary fibrosis. A potential mechanism for the recruitment and activation of neutrophils in lung fibrosis. J Clin Invest. 1991 Dec;88(6):1802–1810. doi: 10.1172/JCI115501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Donnelly S. C., Strieter R. M., Kunkel S. L., Walz A., Robertson C. R., Carter D. C., Grant I. S., Pollok A. J., Haslett C. Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups. Lancet. 1993 Mar 13;341(8846):643–647. doi: 10.1016/0140-6736(93)90416-e. [DOI] [PubMed] [Google Scholar]
  8. Fick R. B., Jr, Naegel G. P., Squier S. U., Wood R. E., Gee J. B., Reynolds H. Y. Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis. J Clin Invest. 1984 Jul;74(1):236–248. doi: 10.1172/JCI111407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Fick R. B., Jr, Robbins R. A., Squier S. U., Schoderbek W. E., Russ W. D. Complement activation in cystic fibrosis respiratory fluids: in vivo and in vitro generation of C5a and chemotactic activity. Pediatr Res. 1986 Dec;20(12):1258–1268. doi: 10.1203/00006450-198612000-00014. [DOI] [PubMed] [Google Scholar]
  10. Fuchs H. J., Borowitz D. S., Christiansen D. H., Morris E. M., Nash M. L., Ramsey B. W., Rosenstein B. J., Smith A. L., Wohl M. E. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994 Sep 8;331(10):637–642. doi: 10.1056/NEJM199409083311003. [DOI] [PubMed] [Google Scholar]
  11. Khan T. Z., Wagener J. S., Bost T., Martinez J., Accurso F. J., Riches D. W. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med. 1995 Apr;151(4):1075–1082. doi: 10.1164/ajrccm/151.4.1075. [DOI] [PubMed] [Google Scholar]
  12. LIEBERMAN J., TRIMMER B. M., KURNICK N. B. SUBSTRATE SPECIFICITY OF PROTEASE ACTIVITIES IN PURULENT SPUTUM. Lab Invest. 1965 Mar;14:249–257. [PubMed] [Google Scholar]
  13. Lieberman J. Dornase aerosol effect on sputum viscosity in cases of cystic fibrosis. JAMA. 1968 Jul 29;205(5):312–313. [PubMed] [Google Scholar]
  14. Nakamura H., Yoshimura K., McElvaney N. G., Crystal R. G. Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J Clin Invest. 1992 May;89(5):1478–1484. doi: 10.1172/JCI115738. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. O'Connor C. M., Gaffney K., Keane J., Southey A., Byrne N., O'Mahoney S., Fitzgerald M. X. alpha 1-Proteinase inhibitor, elastase activity, and lung disease severity in cystic fibrosis. Am Rev Respir Dis. 1993 Dec;148(6 Pt 1):1665–1670. doi: 10.1164/ajrccm/148.6_Pt_1.1665. [DOI] [PubMed] [Google Scholar]
  16. Ranasinha C., Assoufi B., Shak S., Christiansen D., Fuchs H., Empey D., Geddes D., Hodson M. Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis. Lancet. 1993 Jul 24;342(8865):199–202. doi: 10.1016/0140-6736(93)92297-7. [DOI] [PubMed] [Google Scholar]
  17. Raskin P. Bronchospasm after inhalation of pancreatic dornase. Am Rev Respir Dis. 1968 Oct;98(4):697–698. doi: 10.1164/arrd.1968.98.4.697. [DOI] [PubMed] [Google Scholar]
  18. Shah P. L., Scott S. F., Fuchs H. J., Geddes D. M., Hodson M. E. Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I. Thorax. 1995 Apr;50(4):333–338. doi: 10.1136/thx.50.4.333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Shah P. L., Scott S. F., Geddes D. M., Hodson M. E. Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis. Respir Med. 1995 Aug;89(7):499–502. doi: 10.1016/0954-6111(95)90126-4. [DOI] [PubMed] [Google Scholar]
  20. Shak S., Capon D. J., Hellmiss R., Marsters S. A., Baker C. L. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci U S A. 1990 Dec;87(23):9188–9192. doi: 10.1073/pnas.87.23.9188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Suter S., Schaad U. B., Roux L., Nydegger U. E., Waldvogel F. A. Granulocyte neutral proteases and Pseudomonas elastase as possible causes of airway damage in patients with cystic fibrosis. J Infect Dis. 1984 Apr;149(4):523–531. doi: 10.1093/infdis/149.4.523. [DOI] [PubMed] [Google Scholar]
  22. Suter S., Schaad U. B., Tegner H., Ohlsson K., Desgrandchamps D., Waldvogel F. A. Levels of free granulocyte elastase in bronchial secretions from patients with cystic fibrosis: effect of antimicrobial treatment against Pseudomonas aeruginosa. J Infect Dis. 1986 May;153(5):902–909. doi: 10.1093/infdis/153.5.902. [DOI] [PubMed] [Google Scholar]
  23. Thomson A. H. Human recombinant DNase in cystic fibrosis. J R Soc Med. 1995;88 (Suppl 25):24–29. [PMC free article] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES